High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review

BACKGROUND: Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated by immune-related adverse events (irAEs), in...

Descripción completa

Detalles Bibliográficos
Autores principales: Koyama, N., Iwase, O., Nakashima, E., Kishida, K., Kondo, T., Watanabe, Y., Takahashi, H., Umebayashi, Y., Ogawa, Y., Miura, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789617/
https://www.ncbi.nlm.nih.gov/pubmed/29378571
http://dx.doi.org/10.1186/s12890-018-0592-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789617/
https://www.ncbi.nlm.nih.gov/pubmed/29378571
http://dx.doi.org/10.1186/s12890-018-0592-x

Ejemplares similares